BATON ROUGE, La. (BRPROUD) — LSU researchers have created a COVID-19 pill by using artificial intelligence (AI). Now that pill has been accepted for clinical trials.
According to one person part of the research team, Dr. Supratik Mukhopadhyay, LSU researchers have been working on this pill since the start of the pandemic.
“We’re excited to partner with RUHS and Dr. Bruce Weng’s team to facilitate a human clinical investigation to try to demonstrate the safety of the drug combination and efficacy in adult patients who have tested positive for COVID-19 and exhibit mild-to-moderate symptoms,” said Kishor Wasan, chief medical and scientific officer at Skymount Medical.
According to LSU, the study will be a double-blind intervention conducted in an outpatient setting. The trial will compare the two-drug combination to a placebo.
The goal of the study is to determine the impact this combination therapy will have on decreasing the length and severity of symptoms without negative side effects.
Similar trials like this are already taking place in Europe. On Friday Pfizer announced their antiviral pill for COVID-19 could cut hospitalization and death rates by nearly 90%. Pfizer is waiting on the FDA to authorize the pill.
The only treatment available for COVID-19 is the monoclonal antibody treatment. Mukhopadhyay still recommends the COVID vaccine for prevention, but he said a pill may help those who have a breakthrough case.
“It’s very gratifying to see this medication enter into the human study phase,” Mukhopadhyay said. “The fact that we are at this stage so quickly is due to Skymount Medical’s vast professional medical network and our DeepDrug platform, which was able to identify this particular combination of medications in a fraction of the time that traditional research takes.”
Researchers are hoping for a successful trial and should have the results by the beginning of next year.